Holen Sie sich die Stockscreener-App
0.3519
6.76%
-0.0255
Handel nachbörslich:
.36
0.0081
+2.30%
Schlusskurs vom Vortag:
$0.3774
Offen:
$0.3683
24-Stunden-Volumen:
6.33M
Relative Volume:
2.37
Marktkapitalisierung:
$67.19M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-58.01M
KGV:
-0.4274
EPS:
-0.8234
Netto-Cashflow:
$-46.68M
1W Leistung:
-41.93%
1M Leistung:
-55.21%
6M Leistung:
-72.93%
1J Leistung:
-71.85%
1-Tages-Spanne:
$0.3033
$0.3748
1-Wochen-Bereich:
$0.3033
$0.5687
52-Wochen-Spanne:
$0.3033
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Firmenname
Lucid Diagnostics Inc
Sektor
Branche
Telefon
212 949 4319
Adresse
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.3519 | 67.19M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
102.45 | 177.28B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.63 | 121.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
304.40 | 116.76B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.58 | 66.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.29 | 50.89B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Eingeleitet | BTIG Research | Buy |
| 2021-11-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Needham | Buy |
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics Receives Nasdaq Notice for Sub-$1 Bid Price, Faces Compliance Deadline - Kalkine Media
Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Finansavisen
A new billing code was approved for a tool that collects esophageal cells. Medicare payment remains pending. - Stock Titan
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Yahoo Finance
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9.5 - Moomoo
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - AOL.com
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Sahm
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Benzinga
LUCD Q1 2026 Earnings: EPS Misses by 100.7% as Commercialization Costs MountROIC Trend Report - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - Yahoo Finance
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com India
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93SMA Signal - dars.gov.et
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93Imbalance Zone - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Finansavisen
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportUnusual Put Volume - vinanet.vn
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Lucid Diagnostics Q2 Earnings Call Highlights - Yahoo Finance
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Nigeria
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com India
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Canada
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com UK
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
Finanzdaten der Lucid Diagnostics Inc-Aktie (LUCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
1.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):